Clonal expansion and linear genome evolution through breast cancer progression from pre-invasive stages to asynchronous metastasis.
Evolution of the breast cancer genome from pre-invasive stages to asynchronous metastasis is complex and mostly unexplored, but highly demanded as it may provide novel markers for and mechanistic insights in cancer progression. The increasing use of personalized therapy of breast cancer necessitates knowledge of the degree of genomic concordance between different steps of malignant progression as primary tumors often are used as surrogates of systemic disease. Based on exome sequencing we performed copy number profiling and point mutation detection on successive steps of breast cancer progression from one breast cancer patient, including two different regions of Ductal Carcinoma In Situ (DCIS), primary tumor and an asynchronous metastasis. We identify a remarkable landscape of somatic mutations, retained throughout breast cancer progression and with new mutational events emerging at each step. Our data, contrary to the proposed model of early dissemination of metastatic cells and parallel progression of primary tumors and metastases, provide evidence of linear progression of breast cancer with relatively late dissemination from the primary tumor. The genomic discordance between the different stages of tumor evolution in this patient emphasizes the importance of molecular profiling of metastatic tissue directing molecularly targeted therapy at recurrence.
Department of Clinical Genetics, Odense University Hospital, 5000 Odense C, Denmark.|Human Genetics, Institute of Clinical Research, University of Southern Denmark, 5000 Odense C, Denmark.
Anne Bruun
AB
Krøigård
Department of Clinical Genetics, Odense University Hospital, 5000 Odense C, Denmark.|Human Genetics, Institute of Clinical Research, University of Southern Denmark, 5000 Odense C, Denmark.
Martin Jakob
MJ
Larsen
Department of Pathology, Slagelse Hospital, 4200 Slagelse, Denmark.
Anne-Vibeke
AV
Lænkholm
Department of Oncology, Rigshospitalet, 2100 Copenhagen, Denmark.
Ann S
AS
Knoop
Department of Oncology, Odense University Hospital, 5000 Odense C, Denmark.
Jeanette D
JD
Jensen
Department of Pathology, Odense University Hospital, 5000 Odense C, Denmark.
Martin
M
Bak
Lundbeckfonden Center of Excellence NanoCAN, 5000 Odense C, Denmark.|Molecular Oncology Group, Institute of Molecular Medicine, University of Southern Denmark, 5000 Odense C, Denmark.
Jan
J
Mollenhauer
Department of Clinical Genetics, Odense University Hospital, 5000 Odense C, Denmark.|Human Genetics, Institute of Clinical Research, University of Southern Denmark, 5000 Odense C, Denmark.|Lundbeckfonden Center of Excellence NanoCAN, 5000 Odense C, Denmark.
Torben A
TA
Kruse
Department of Clinical Genetics, Odense University Hospital, 5000 Odense C, Denmark.|Human Genetics, Institute of Clinical Research, University of Southern Denmark, 5000 Odense C, Denmark.|Lundbeckfonden Center of Excellence NanoCAN, 5000 Odense C, Denmark.
Mads
M
Thomassen
D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology*; D056915:DNA Copy Number Variations; D018450:Disease Progression; D004812:Epidemiologic Methods; D005260:Female; D016678:Genome; D006801:Humans; D016014:Linear Models; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging
breast cancer; copy number aberrations; linear progression model; metastasis models